Update on Pharmacotherapy for Pulmonary Hypertension
Pulmonary arterial hypertension (PAH) is a rare disease with a poor prognosis if not treated. Pharmacological treatment options for PAH have increased significantly over the past 10 years, with availability of intravenous, oral and inhaled drugs targeting the nitric oxide, endothelin and prostacyclin pathways.
This module includes an evidence-based overview of PAH treatment as applied to clinical practice, focusing on Group 1 and Group 4 PH (for which there is good evidence for pharmacological treatment).
Medical Journal of Australia
Reading: journal; textbook; book; literature review
1h : 0m
MBA: 1h : 0m
Medical Practitioner, Medical Student, Doctor-in-Training, Non-Vocationally Registered, Nurse / Midwife, Pharmacist, Podiatrist, Researcher, Retired, Specialist - Other, Specialist General Practitioner